These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1105111)

  • 21. Bioavailability of phenytoin: a comparison between two preparations.
    Zylber-Katz E; Granit L; Levy M
    Isr J Med Sci; 1978 Apr; 14(4):489-91. PubMed ID: 352994
    [No Abstract]   [Full Text] [Related]  

  • 22. Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).
    Atef E; Belmonte AA
    Eur J Pharm Sci; 2008 Nov; 35(4):257-63. PubMed ID: 18706499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of relative humidity on drug release from phenytoin sodium tablets and capsules. Part 1: Commercial preparations.
    Akbuğa J; Ari-Ulubelen A; Bayraktar-Alpmen G
    Pharmazie; 1984 Aug; 39(8):560-1. PubMed ID: 6504981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
    Shah J; Wesnes KA; Kovelesky RA; Henney HR
    Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the bioavailability of Polfa phenytoin tablets].
    Lazowski J; Lypka A; Zadrozyńska E; Pakszys W
    Neurol Neurochir Pol; 1978; 12(3):251-5. PubMed ID: 683430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects.
    Yong CS; Oh YK; Lee KH; Park SM; Park YJ; Gil YS; Yu CH; Yoo BK; Woo JS; Kim JO; Rhee JD; Kim CK; Choi HG
    Int J Pharm; 2005 Sep; 302(1-2):78-83. PubMed ID: 16107306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of phenytoin: comparison between three preparations.
    Kitzes R; Ackerman Z; Levy M; Frumerman I; Shved A; Garty M
    Isr J Med Sci; 1985 Apr; 21(4):323-6. PubMed ID: 3997494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenytoin toxicity when tablets substituted for capsules.
    Kirshner HS
    N Engl J Med; 1983 May; 308(18):1106. PubMed ID: 6835331
    [No Abstract]   [Full Text] [Related]  

  • 29. Absolute bioavailability of quinine formulations in Nigeria.
    Babalola CP; Bolaji OO; Ogunbona FA; Ezeomah E
    Afr J Med Med Sci; 2004 Sep; 33(3):185-9. PubMed ID: 15819461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR; Shah J
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability and dissolution of proprietary and generic formulations of phenytoin.
    Soryal I; Richens A
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):688-91. PubMed ID: 1527539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced seizure control due to spoiled phenytoin capsules.
    Cloyd JC; Gumnit RJ; Lesar TS
    Ann Neurol; 1980 Feb; 7(2):191-3. PubMed ID: 7369725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum hydantoin levels with various proprietary preparations.
    Ahuja GK; Ali SR; Rao BS; Mani KS
    Neurol India; 1973 Sep; 21(3):119-23. PubMed ID: 4784814
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study.
    Rojanasthien N; Chaichana N; Teekachunhatean S; Kumsorn B; Sangdee C; Chankrachang S
    J Med Assoc Thai; 2007 Sep; 90(9):1883-93. PubMed ID: 17957935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of serum phenytoin levels in epileptic patients who swallowed their phenytoin tablets with or without previous chewing.
    Bielmann P; Levac T
    Eur J Clin Pharmacol; 1978 Nov; 14(3):191-4. PubMed ID: 729613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.
    Rambeck B; Boenigk HE; Stenzel E
    Eur J Clin Pharmacol; 1977 Dec; 12(4):285-90. PubMed ID: 579344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules.
    Michos N; Zulliger HW; Barkworth MF; Johnson KJ; Rehm KD; Töberich H; Klein G
    Arzneimittelforschung; 1986 Jun; 36(6):941-8. PubMed ID: 3741528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies of the biological availability of phenytoin preparations (Polfa) and micronized phenytoin in patients with cardiac rhythm disorders].
    Wierzchowiecki M; Swiderczuk A; Dyderski S; Masiakowski J; Jazienicki B
    Kardiol Pol; 1987; 30(9):577-82. PubMed ID: 2447321
    [No Abstract]   [Full Text] [Related]  

  • 39. Absorption characteristics of three phenytoin sodium products after administration of oral loading doses.
    Goff DA; Spunt AL; Jung D; Bellur SN; Fischer JH
    Clin Pharm; 1984; 3(6):634-8. PubMed ID: 6509876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of bioavailabilities of different phenytoin preparations.
    Fukuyama Y; Kitahara H; Goto T
    Brain Dev; 1982; 4(1):35-43. PubMed ID: 7065375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.